EMA reports on Good Clinical Practice inspection reports

Published: 26-Jan-2015
Regulatory

Aims to help categorise such investigations in the future


The European Medicines Agency has released a report classifying the findings of good clinical practice (GCP) inspection reports from 2000–2012, with the aim of helping to categorise such probes in future.

The classification includes finding, grading, category, responsibility and reference to international and other guidelines. It also analyses reports by procedures, products, sites involved, inspection dates and inspectors’ details.

  • Companies:
  • EMA European Medicines Agency
See more

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Read more
Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency

Trending Articles

  1. FDA releases guidance to clarify guidelines for 'remanufacturing' devices that need maintenance or repair The guidelines includes information on reusable product labelling, what it classifies as 'remanufacturing' and how companies can ensure products follow guidelines after multiple uses
  2. WestGene's mRNA therapeutic cancer vaccine receives FDA approval The novel mRNA therapeutic is the first EB virus-related cancer vaccine to be approved by the FDA
  3. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  4. Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary endpoints
  5. How to proactively address EU HTAR implementation challenges before 2025 Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts

Upcoming event

BIO International Convention Digital

3-6 June, 2024 | Convention | San Diego, US See all

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Regulatory

EMA celebrates 25 years of regulatory management

The EMA was founded in January 1995
Regulatory

EMA publishes draft guideline on quality requirements for DDCs

The latest document focuses on combinations of medicinal products and medical devices
Regulatory

GMP inspection in Bulgaria and Cyprus now on par with US

A mutual recognition agreement between the EU and the US regulatory bodies aims to encompass all EU member states, now standing at 24 of the 28
Regulatory

Brexit update: UK Inspection Reports and GMP Certificates

The ECA Academy sheds light on the latest Brexit guidance documents released by the European Medicines Agency
Regulatory

Poland and Slovenia join EU-US mutual recognition agreement for inspections

GMP drug plant inspections conducted by health authorities in Poland and Slovenia will now be accepted by the US FDA
Subscribe now